chamber, patient, hyperbaric
emergo asia pacific pty ltd t/a emergo australia -
trental
sanofi-aventis australia pty ltd - oxpentifylline -
trental
sanofi-aventis new zealand limited - pentoxifylline 400mg - modified release tablet - 400 mg - active: pentoxifylline 400mg excipient: acacia erythrosine hyetellose macrogol 6000 magnesium stearate povidone purified talc sucrose titanium dioxide
trental
clinect nz pty limited - pentoxifylline 400mg; ; - modified release tablet - 400 mg - active: pentoxifylline 400mg excipient: erythrosine hyetellose hypromellose macrogol 8000 magnesium stearate povidone purified talc purified water titanium dioxide - the treatment of peripheral occlusive vascular disease and circulatory disorders of arteriosclerotic, diabetic, inflammatory or function origin; trophic disorders (e.g., leg ulcers and gangrene).
trental 400 pentoxifylline (oxpentifylline) 400 mg modified release tablet blister pack
clinect pty ltd - pentoxifylline, quantity: 400 mg - tablet, modified release - excipient ingredients: povidone; hyetellose; titanium dioxide; hypromellose; erythrosine; purified talc; macrogol 8000; magnesium stearate - treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. trental 400 can thus improve function and symptoms but is not intended to replace more definitive therapy, such as vascular surgery, or removal of arterial obstructions when treating peripheral vascular disease.
apo-doxycycline 100mg (as monohydrate) tablet blister pack
apotex pty ltd - doxycycline monohydrate -
trental tablet (extended-release)
sanofi-aventis canada inc - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents
ratio-pentoxifylline tablet (extended-release)
ratiopharm inc division of teva canada limited - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents
pentoxifylline tablet, extended release
bryant ranch prepack - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet extended release
teva pharmaceuticals usa inc - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg